We also found a significant ability to predict SMARCA4-d by the number of SBS signature 27 mutations in cancers of the neuro-endocrine tissues (Wilcoxon test, one-tailed p = 0.002) and head and neck (p = 4.8 × 10−7), but we could not evaluate this in lung cancers, as the signature is not among its set of cohort-specific signatures. Here, SMARCA4 is linked to lung carcinoma.